相关实验视频
Updated: Jan 13, 2026

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
2.1K
阿尔茨海默病中的神经精神症状:过去,现在和未来
Constantine G Lyketsos1, Matthew E Peters1
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
概括
非认知神经精神症状 (NPS) 显著影响阿尔茨海默病 (AD) 患者和照顾者,加速痴呆症的进展. 研究进展,包括轻度行为障碍 (MBI) 构造,正在改善对ADNPS的理解和治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 精神病学是一个精神病学.
背景情况:
- 非认知神经精神症状 (NPS) 在阿尔茨海默病 (AD) 中很普遍,对患者和护理人员产生负面影响,并且与疾病进展的加快有关.
- 阿洛伊斯·阿尔茨海默对NPS的历史认可强调了它们长期以来的临床意义.
研究的目的:
- 审查了解和治疗阿尔茨海默病中NPS的进展.
- 要突出轻度行为障碍 (MBI) 构造的发展,作为痴呆症的前体.
- 讨论正在进行的关于NPS神经生物学基础和治疗管道的研究.
主要方法:
- 从2010年代开始的研究圆桌会议和出版物的审查.
- 分析轻度行为障碍 (MBI) 构造的发展和影响.
- 检查关于NPS的神经生物学基础和治疗策略的当前研究.
主要成果:
- 在阿尔茨海默病中,NPS几乎是普遍存在的,并且对疾病的发展轨迹产生重大影响.
- MBI构造提供了一个框架,用于在痴呆症发病之前识别NPS.
- 一个多样化的治疗管道正在出现,包括新药,重新定位的药物和非药物干预.
结论:
- 最近的研究已经大大提高了对阿尔茨海默病中NPS的理解和管理.
- 持续的研究和协作努力对于开发有效的干预措施至关重要.
- 像阿尔茨海默氏病研究中心和国家阿尔茨海默氏病协调中心这样的机构对于NPS研究的进展至关重要.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Negative and Cognitive Symptoms of Schizophrenia
445
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
445
Dementia
511
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
511
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K

